Image (1b0db25b 4dd9 49fc B2b0 B18157d73bca 815 1)
Lurasidone Hydrochloride Tablet
Product Images NDC 70518-4427
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 70518-4427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (98489a2d A33e 49d6 A23f 45932da3f7b0 793 1)
Chemical structure diagram of lurasidone hydrochloride showing its molecular arrangement with rings and bond connections typical of its chemical makeup.*
Remedy_label (Remedy Label)
Label for lurasidone hydrochloride 40 mg tablets shows a quantity of 30 tablets. The tablets are described as round and white. The label indicates repackaging by RemedyRepack Inc., Indiana, PA. Storage instructions specify keeping medication out of children’s reach and preferred temperature ranges. The label includes manufacturer info: Lupin Ltd, Goa, India.*
Image-01 (F34d847a 0e47 4cbf 9d96 B90e1fef1595 01)
Chemical structure of lurasidone hydrochloride showing the molecular arrangement including multiple ring systems, nitrogen, oxygen, hydrogen atoms, and the hydrochloride (HCl) component.*
Image-02 (F34d847a 0e47 4cbf 9d96 B90e1fef1595 02)
A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of lurasidone hydrochloride when co-administered with interacting drugs, including strong CYP3A4 inhibitor ketoconazole, moderate CYP3A4 inhibitor diltiazem, and strong CYP3A4 inducer rifampin, and lithium. The horizontal axis represents change relative to lurasidone alone.*
Image-03 (F34d847a 0e47 4cbf 9d96 B90e1fef1595 03)
A scatter plot with error bars depicting fold change and 90% confidence intervals in pharmacokinetic parameters for various interacting drugs compared to interactive drug alone. It includes data for P-gp substrates (Digoxin 0.25 mg SD), CYP3A4 substrates (Midazolam 5 mg SD), oral contraceptives (Ethinyl Estradiol and Norethindrone), and Lithium 600 mg BID, showing changes in Cmax, AUC, and Ctrough values.*
Image-04 (F34d847a 0e47 4cbf 9d96 B90e1fef1595 04)
A pharmacokinetic chart showing fold change and 90% confidence intervals for lurasidone hydrochloride. It includes data on Cmax and AUC changes relative to reference for renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population descriptions by gender (female) and race (Asian). The x-axis represents change relative to reference values.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
